company background image
SYNH

Syneos Health NasdaqGS:SYNH Stock Report

Last Price

US$47.15

Market Cap

US$4.8b

7D

-1.8%

1Y

-46.0%

Updated

02 Oct, 2022

Data

Company Financials +
SYNH fundamental analysis
Snowflake Score
Valuation6/6
Future Growth2/6
Past Performance4/6
Financial Health3/6
Dividends0/6

SYNH Stock Overview

Syneos Health, Inc. provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America.

Syneos Health, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Syneos Health
Historical stock prices
Current Share PriceUS$47.15
52 Week HighUS$104.18
52 Week LowUS$46.24
Beta1.75
1 Month Change-19.10%
3 Month Change-34.12%
1 Year Change-46.03%
3 Year Change-10.80%
5 Year Change-13.41%
Change since IPO130.11%

Recent News & Updates

Sep 13

Syneos Health falls 13% after update on outlook

The shares of contract research organization Syneos Health, Inc. (NASDAQ:SYNH) dropped ~13% in the morning hours Tuesday after the company projected its Book-to-Bill ratio in the Clinical Solutions business could reach 1.05x – 1.15x for the 12-months ending Sep. 30. The outlook provided ahead of the company's presentation at Tuesday's 2022 Baird Global Healthcare Conference excluded reimbursable expenses. Commenting on the update, Baird analyst Eric Coldwell who has an Outperform rating and an $89 per share target on SYNH, noted that the forecast indicated "further sequential declines in 3Q clinical net awards and NBB [net book-to-bill]." "Challenges appear to be large-client timing and SMID client hesitancy given the macroeconomic environment," Coldwell added. The analyst stopped short of updating his model for SYNH but added he is "leaning toward another round of 2023 reductions," subject to the company's presentation at the event. For 12 months ending Jun. 30, SYNH reported a ~1.29x of Book-to-Bill ratio for the Clinical Solutions business, excluding reimbursable expenses.

Sep 08
When Should You Buy Syneos Health, Inc. (NASDAQ:SYNH)?

When Should You Buy Syneos Health, Inc. (NASDAQ:SYNH)?

Syneos Health, Inc. ( NASDAQ:SYNH ), is not the largest company out there, but it saw significant share price movement...

Aug 22
Is Syneos Health (NASDAQ:SYNH) A Risky Investment?

Is Syneos Health (NASDAQ:SYNH) A Risky Investment?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Shareholder Returns

SYNHUS Life SciencesUS Market
7D-1.8%-1.9%-2.5%
1Y-46.0%-32.0%-23.2%

Return vs Industry: SYNH underperformed the US Life Sciences industry which returned -31.9% over the past year.

Return vs Market: SYNH underperformed the US Market which returned -23.2% over the past year.

Price Volatility

Is SYNH's price volatile compared to industry and market?
SYNH volatility
SYNH Average Weekly Movement7.5%
Life Sciences Industry Average Movement9.7%
Market Average Movement6.8%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: SYNH is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: SYNH's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201026,751Michelle Keefehttps://www.syneoshealth.com

Syneos Health, Inc. provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in the Phase I to IV of clinical development.

Syneos Health, Inc. Fundamentals Summary

How do Syneos Health's earnings and revenue compare to its market cap?
SYNH fundamental statistics
Market CapUS$4.84b
Earnings (TTM)US$278.12m
Revenue (TTM)US$5.42b

17.4x

P/E Ratio

0.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
SYNH income statement (TTM)
RevenueUS$5.42b
Cost of RevenueUS$4.14b
Gross ProfitUS$1.28b
Other ExpensesUS$1.00b
EarningsUS$278.12m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)2.71
Gross Margin23.67%
Net Profit Margin5.13%
Debt/Equity Ratio84.5%

How did SYNH perform over the long term?

See historical performance and comparison